NextCell Pharma AB (NXTCL)

Overview

NextCell Pharma AB is a pioneering biopharmaceutical entity centered on the development and manufacture of innovative stromal cell therapies. With its foundation laid in 2014 and headquartered in Huddinge, Sweden, the company stands at the forefront of harnessing the potential of stem cells to address unmet medical needs. Predominantly focusing on the realm of autoimmune diseases, such as type-1 diabetes, NextCell Pharma AB leverages cutting-edge scientific research to propel advancements in medical treatments through cellular therapies. In addition to its robust research and development activities, the company contributes to the healthcare ecosystem through Cellaviva, its stem cell banking division, aimed at preserving stem cells for future therapeutic needs.

Products and Services

• ProTrans

At the core of NextCell Pharma AB's product pipeline lies ProTrans, a drug candidate that signifies a breakthrough in immunotherapy. ProTrans is developed from stem cells with the ambitious goal of treating autoimmune diseases, most notably type-1 diabetes. This novel therapeutic approach embodies the company's commitment to leveraging the regenerative capabilities of stromal cells, aiming to provide a significant stride forward in the treatment of diseases with high unmet medical needs.

• Cellaviva

Underpinning NextCell Pharma AB's service offering, Cellaviva emerges as Sweden's first private initiative for stem cell banking. Cellaviva offers a service that allows families to store stem cells derived from umbilical cord blood and tissue at the time of childbirth. These preserved cells can be a crucial resource for the treatment of various diseases through regenerative medicine in the future, emphasizing the company's dedication to advancing healthcare solutions through the innovative use of stem cells.